Sanofi 买Dynavax $2.2B 来增加成人疫苗, 2026年初关闭。 Sanofi to buy Dynavax for $2.2B to boost adult vaccines, closing early 2026.

Sanofi同意在22亿美元的全部现金交易中购买疫苗开发商Dynavax Technologies(Dynavax Technology), 每股15.5美元, Sanofi has agreed to acquire vaccine developer Dynavax Technologies in a $2.2 billion all-cash deal, offering $15.50 per share, a 39% premium over Dynavax’s prior closing price. 此次采购预期于2026年初结束, 并增加Dynavax市场销售的乙型肝炎疫苗(HEPLISAV-B), 以及萨诺菲早期临床试验的针线疫苗候选者。 The acquisition, expected to close in early 2026, adds Dynavax’s marketed hepatitis B vaccine, HEPLISAV-B, and a shingles vaccine candidate in early clinical trials to Sanofi’s portfolio. 这一举动旨在加强赛诺菲在最近的监管挫折和推动其超越最销药物Dupixent的多样化中提供成年免疫. The move aims to strengthen Sanofi’s adult immunization offerings amid recent regulatory setbacks and a push to diversify beyond its top-selling drug, Dupixent. 预计这笔交易不会影响Sanofi的2025年财务指导。 The transaction is not expected to impact Sanofi’s 2025 financial guidance.